We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+27.77%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$8.73B
AUM Growth
+$1.49B
Cap. Flow
+$225M
Cap. Flow %
2.57%
Top 10 Hldgs %
31.85%
Holding
234
New
17
Increased
80
Reduced
68
Closed
12

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$143M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$63.9M
3
MRSN
Mersana Therapeutics
MRSN
+$42.8M
4
DXCM icon
DexCom
DXCM
+$32.7M
5
ABBV icon
AbbVie
ABBV
+$32.5M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$154M
2
HALO icon
Halozyme
HALO
+$51.2M
3
CRL icon
Charles River Laboratories
CRL
+$49.6M
4
CDNA icon
CareDx
CDNA
+$44.7M
5
MDT icon
Medtronic
MDT
+$40.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.9%
2 Technology 0.6%
3 Industrials 0.33%
4 Financials 0.11%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QTTB icon
101
Q32 Bio
QTTB
$450M
$19.6M 0.22%
96,507
– –
VYGR icon
102
Voyager Therapeutics
VYGR
$187M
$19.4M 0.22%
2,712,083
– –
ILMN icon
103
Illumina
ILMN
$29.4B
$19.4M 0.22%
53,832
-6,354
-11% -$2.03M
ACCD
104
DELISTED
Accolade Inc
ACCD
$16.8M 0.19%
385,308
+175,981
+84% +$7.82M
COO icon
105
Cooper Companies
COO
$13.7B
$15.8M 0.18%
174,040
+72,660
+72% +$6.23M
AVTR icon
106
Avantor
AVTR
$7.81B
$14.4M 0.17%
512,216
+205,127
+67% +$5.29M
CELL
107
DELISTED
PhenomeX Inc. Common Stock
CELL
$14.4M 0.16%
160,505
+52,995
+49% +$4.46M
XENT
108
DELISTED
Intersect ENT, Inc
XENT
$14.2M 0.16%
619,481
+146,099
+31% +$2.78M
OXFD
109
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$14M 0.16%
800,157
– –
REGN icon
110
Regeneron Pharmaceuticals
REGN
$68.8B
$13.4M 0.15%
27,700
+7,700
+39% +$4.16M
TMDX icon
111
Transmedics
TMDX
$2.5B
$12.8M 0.15%
641,612
+64,465
+11% +$954K
LUNG icon
112
Pulmonx
LUNG
$49.4M
$12.2M 0.14%
+176,510
New +$8.64M
LEGN icon
113
Legend Biotech
LEGN
$4.3B
$11.7M 0.13%
+416,341
New +$12M
VCRA
114
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$11.1M 0.13%
268,171
+66,781
+33% +$2.29M
OM icon
115
Outset Medical
OM
$74.9M
$10.8M 0.12%
12,647
+7,319
+137% +$5.64M
NBP
116
NovaBridge Biosciences American Depositary Shares
NBP
$205M
$9.58M 0.11%
203,212
+138,212
+213% +$5.44M
TRHC
117
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
$9.34M 0.11%
217,975
-26,494
-11% -$1.01M
EAR
118
DELISTED
Eargo, Inc. Common Stock
EAR
$8.81M 0.1%
+9,826
New +$8.28M
XRAY icon
119
Dentsply Sirona
XRAY
$2.59B
$8.33M 0.1%
159,129
– –
CVS icon
120
CVS Health
CVS
$137B
$8.24M 0.09%
120,595
-66,386
-36% -$4.32M
SGEN
121
DELISTED
Seagen Inc. Common Stock
SGEN
$8.16M 0.09%
46,600
– –
INGN icon
122
Inogen
INGN
$167M
$8M 0.09%
179,143
+30,231
+20% +$1.04M
RARE icon
123
Ultragenyx Pharmaceutical
RARE
$2.65B
$5.68M 0.07%
41,000
– –
CDTX
124
DELISTED
Cidara Therapeutics
CDTX
$5.64M 0.06%
141,125
– –
GILD icon
125
Gilead Sciences
GILD
$161B
$4.93M 0.06%
84,600
-39,100
-32% -$2.36M
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2020 Portfolio in Review

As of Q4 2020, Bellevue Group held 234 positions worth $8.73B, up 21% from $7.24B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Bellevue Group's Q4 2020 filing shows 17 new, 80 increased, 68 reduced and 12 closed positions. Its largest new stake was Mersana Therapeutics: 77,040 shares worth $51.3M. The largest sale was MyoKardia, Inc. Common Stock, an estimated $154M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Technology and Industrials.

  • Bellevue Group's largest Q4 2020 buy was Mersana Therapeutics: 77,040 shares worth $51.3M.
  • Bellevue Group added most to Biogen in Q4 2020, an estimated $143M increase.
  • Bellevue Group's biggest Q4 2020 reduction was Halozyme, cutting an estimated $51.2M.
  • Bellevue Group fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $154M.
  • Bellevue Group's ten largest holdings make up 32% of its $8.73B portfolio in Q4 2020.
  • Bellevue Group opened 17 new positions and closed 12 in Q4 2020.
  • Bellevue Group's portfolio value rose 21% quarter-over-quarter to $8.73B.

Based on Bellevue Group's 13F filing for Q4 2020, filed 16 Feb 2021.